Explore the words cloud of the MESI-STRAT project. It provides you a very rough idea of what is the project "MESI-STRAT" about.
The following table provides information about the project.
|Coordinator Country||Austria [AT]|
|Total cost||5˙949˙963 €|
|EC max contribution||5˙949˙963 € (100%)|
1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
|Duration (year-month-day)||from 2018-01-01 to 2022-09-30|
Take a look of project's partnership.
|1||UNIVERSITAET INNSBRUCK||AT (INNSBRUCK)||coordinator||1˙609˙163.00|
|2||DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG||DE (HEIDELBERG)||participant||870˙100.00|
|3||UNIVERSITETET I BERGEN||NO (BERGEN)||participant||679˙520.00|
|4||CHARITE - UNIVERSITAETSMEDIZIN BERLIN||DE (BERLIN)||participant||398˙706.00|
|5||UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET||NO (TROMSO)||participant||366˙925.00|
|6||UNIVERSITATSKLINIKUM HEIDELBERG||DE (HEIDELBERG)||participant||353˙682.00|
|7||DE DUVE INSTITUTE||BE (BRUXELLES)||participant||289˙000.00|
|8||UNIVERSITY OF NEWCASTLE UPON TYNE||UK (NEWCASTLE UPON TYNE)||participant||258˙687.00|
|9||STIFTUNG PATIENTS TUMORBANK OF HOPE- DIE PATIENTENEIGENE TUMORGEWEBEBANK DER HOFFNUNG (PATH)||DE (AUGSBURG)||participant||250˙550.00|
|10||HITS GGMBH||DE (HEIDELBERG)||participant||224˙687.00|
|11||ACADEMISCH ZIEKENHUIS GRONINGEN||NL (GRONINGEN)||participant||223˙524.00|
|12||FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON||ES (BARCELONA)||participant||190˙956.00|
|13||NEUROIMMUN GMBH||DE (KARLSRUHE)||participant||131˙750.00|
|14||SYSBIOSIM BV||NL (LEIDEN)||participant||102˙711.00|
|15||UNIVERSITY OF DURHAM||UK (DURHAM)||participant||0.00|
Breast cancer (BC) is a complex disease with high prevalence in the EU. 75% of the tumors are estrogen receptor-positive (ER), and are treated with endocrine therapies (ET). MESI-STRAT will develop new concepts for knowledge-based stratification of patients into subgroups with different ET resistance mechanisms. We will establish predictive models for (1) patient stratification prior and during ET; (2) recurrence risk assessment when ending ET; (3) marker panel development to guide targeted therapies for ET-resistant patients; (4) novel ET resistance mechanism-based therapy design.
The unique collection of matched BC tissue, serum, and >10 years follow-up from the patient organization PATH is essential for the longitudinal analysis of ET resistance and relapse. Our team of oncologists, modelers, bioinformaticians and experimentalists will develop new computational models in combination with network analyses and pharmacogenomics, to integrate multi-omics data and explore metabolic and signaling (MESI) networks driving ET resistance. Metabolite marker panels measured in biological fluids will enable patient stratification, resistance monitoring and clinical decision-making. This is a new concept as BC metabolism is poorly explored for diagnostics and therapy. Upon successful validation in preclinical models, the predictive marker panels and related treatments will be jointly investigated by our clinical and industrial partners in clinical studies. Our 3 SMEs will closely co-develop the research, and directly exploit the MESI-STRAT results. BC accounts for the highest cancer-related health-care costs in the EU. Our stratification concepts will increase cost effectiveness and the patients’ quality of life by (1) avoiding ineffective therapies, (2) marker detection in body fluids without surgical interventions, and (3) reducing clinical trial cohorts by improved stratification. This will accelerate the translation of MESI-STRAT results into medical use.
|MESI-STRAT website with continuous updates||Websites, patent fillings, videos etc.||2020-04-07 22:43:30|
Take a look to the deliverables list in detail: detailed list of MESI-STRAT deliverables.
|year||authors and title||journal||last update|
Mayra Diosa-Toro, Berit Troost, Denise van de Pol, Alexander Martin Heberle, Silvio Urcuqui-Inchima, Kathrin Thedieck, Jolanda M. Smit
Tomatidine, a novel antiviral compound towards dengue virus
published pages: 90-99, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2018.11.011
|Antiviral Research 161||2020-04-07|
Mahdi Shafiee Kamalabad, Alexander Martin Heberle, Kathrin Thedieck, Marco Grzegorczyk
Partially non-homogeneous dynamic Bayesian networks based on Bayesian regression models with partitioned design matrices
published pages: 2108-2117, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/bty917
Michael Platten, Ellen A. A. Nollen, Ute F. RÃ¶hrig, Francesca Fallarino, Christiane A. Opitz
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
published pages: 379-401, ISSN: 1474-1776, DOI: 10.1038/s41573-019-0016-5
|Nature Reviews Drug Discovery 18/5||2020-04-07|
Alexander Martin Heberle, Patricia Razquin Navas, Miriam Langelaar-Makkinje, Katharina Kasack, Ahmed Sadik, Erik Faessler, Udo Hahn, Philip Marx-Stoelting, Christiane A Opitz, Christine Sers, Ines Heiland, Sascha SchÃ¤uble, Kathrin Thedieck
The PI3K and MAPK/p38 pathways control stress granule assembly in a hierarchical manner
published pages: e201800257, ISSN: 2575-1077, DOI: 10.26508/lsa.201800257
|Life Science Alliance 2/2||2020-04-07|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MESI-STRAT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MESI-STRAT" are provided by the European Opendata Portal: CORDIS opendata.